Accelerating biomedical innovation: a case study of the SPARK program at Stanford University, School of Medicine
Name
AcceleratingBiomedicalInnovation_SPARK_KimOmuraLo_DrugDiscToday26Apr2017-5B2-5D.pdf
Size
255.7 KB
Format
Adobe PDF
Checksum (MD5)
c347b6df34cccb746d5d3fedfe5fea47
Date Issued
March 5, 2019
Journal
Drug Discovery Today
Publisher
Elsevier BV
Citation
Kim, Esther S., Paige M.C. Omura, and Andrew W. Lo. “Accelerating Biomedical Innovation: a Case Study of the SPARK Program at Stanford University, School of Medicine.” Drug Discovery Today 22, no. 7 (July 2017): 1064–1068.
Version
Author's final manuscript
Abstract
Translating academic medical research into new therapies is an important challenge for the biopharmaceutical industry and investment communities, which have historically favored later-stage assets with lower risk and clearer commercial value. The Stanford SPARK program is an innovative model for addressing this challenge. The program was created in 2006 to educate students and faculty about bringing academic research from bench to bedside. Every year, the program provides mentorship and funding for approximately a dozen SPARK ‘scholars,’ with a focus on impacting patient lives, regardless of economic factors. By reviewing the detailed structure, function and operation of SPARK we hope to provide a template for other universities and institutions interested in de-risking and facilitating the translation of biomedical research.
MIT Department
Massachusetts Institute of Technology. Computer Science and Artificial Intelligence Laboratory
Massachusetts Institute of Technology. Department of Chemical Engineering
Massachusetts Institute of Technology. Department of Electrical Engineering and Computer Science
Sloan School of Management
Terms of Use
Creative Commons Attribution-NonCommercial-NoDerivs License
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1016/J.DRUDIS.2017.03.015
